Provention Bio yesterday closed its initial public offering, raising approximately $63.9 million.
Funds from the round will help support the Oldwick, N.J.-based company’s clinical-stage biopharmaceuticals that aim to prevent or intercept immune-mediated diseases.
Read the whole story on our sister site, Drug Delivery Business News
The post Provention Bio closes $64m IPO appeared first on MassDevice.